Rectal administration of nanosystems: from drug delivery to diagnostics

The rectal administration of drugs has been an enduring medical practice for either the management of local or systemic conditions. Although mostly regarded as an alternative to other delivery routes, the colorectal mucosa offers an effective pathway for enhanced systemic bioavailability of many active molecules. The fairly stable physicochemical and enzymatic environment of the mucosa and the possibility of partially avoiding the hepatic first-pass effect are some of the potential advantages of rectal drug delivery. At the same time, higher drug levels of drugs can be achieved at colorectal fluids and tissues, which can aid management of local conditions. However, problems with patient acceptability as well as poor and erratic drug absorption may impair efficient use of the rectal drug delivery route. The valuable features of nanotechnology-based systems for mucosal use are well recognized, and their potential as carriers for drug delivery has already been proven for different medical applications/delivery routes. Although still limited, the development of rectal nanomedicines with therapeutic, diagnostic, and prophylactic purposes is steadily emerging and may circumvent some of the problems associated with the more standard delivery approaches. This review discusses the rationale behind the use of nanotechnology-based strategies for rectal drug delivery and provides a critical overview on the various types of nanosystems proposed so far.     

基于透明质酸的刺激响应纳米给药系统的研究进展

透明质酸(Hyaluronic acid, HA)是一种天然多糖,具有良好的生物相容性和生物降解性,利用 HA 构建的纳米载体自身就具有肿瘤靶向功能,可以作为抗癌药物载体将药物传递到肿瘤细胞内从而实现精准到达病患处。近年来透明质酸在应用于肿瘤靶向给药系统中的关注越来越多,成为了靶向治疗肿瘤的一大研究热点。基于透明质酸的基本特性和肿瘤靶向的生理学基础,在不同的刺激响应下,透明质酸型纳米给药系统能将药物集中释放于肿瘤的微环境内,更好地杀死肿瘤细胞,同时避免其他正常的组织受到药物损害。本文主要综述了透明质酸型纳米药物输送系统在各种刺激响应下释放药物的最新研究进展。     

Singlet Oxygen Induced Site-Specific Etching Boosts Nitrogen-Carbon Sites for High-Efficiency Oxygen Reduction

Targeted construction of carbon defects near the N dopants is an intriguing but challenging way to boost the electrocatalytic activity of N-doped carbon toward oxygen reduction reaction (ORR). Here, we report a novel site-specific etching strategy that features targeted anchoring of singlet oxygen (¹O₂) on the N-adjacent atoms to directionally construct topological carbon defects neighboring the N dopants in N-doped carbon (¹O₂−N/C). This ¹O₂−N/C exhibits the highest ORR half-wave potential of 0.915 V_RHE among all the reported metal-free carbon catalysts. Pyridinic-N bonded with a carbon pentagon of the neighboring topological carbon defects is identified as the primary active configuration, rendering enhanced adsorption of O₂, optimized adsorption energy of the ORR intermediates, and a significantly decreased total energy barrier for ORR. This ¹O₂-induced site-specific etching strategy is also applicable to different precursors, showing a tremendous potential for targeted construction of high-efficiency active sites in carbon-based materials.     

Experimental study of the preparation of targeted microbubble contrast agents carrying urokinase and RGDS

Purpose

To explore the feasibility and the best combined proportion of the preparation of targeted and thrombolytic contrast agents carrying urokinase (UK) and Arg-Gly-Asp-Ser (RGDS), and to study its effect of thrombolysis in vitro.

Methods

Urokinase and RGDS were combined to the surface of SonoVue by direct conjugation method. According to the different ratio of urokinase and RGDS when mixed, they were divided into three groups whose urokinase/RGDS were 1:1, 2:1 and 1:2, respectively. To measure the binding rate of microbubbles and urokinase as well as RGDS by flow cytometry. To detect the effect of thrombolysis by thrombolytic experiment in vitro. To detect the targeting effects by experiment in vivo.

Results

The results of flow cytometry detection showed that the binding rates of urokinase and RGDS of three groups were, respectively, 73.4 ± 11.0% and 67.1 ± 10.9%, 8.8 ± 7.2% and 7.8 ± 6.9%, 49.7 ± 21.3% and 45.9 ± 21.7% after standing for 2 h. In vitro thrombolysis experiment indicated that the urokinase had activity in the prepared contrast agent which the binding rates of urokinase and RGDS were the highest. And it was injected intravenous, the contrast agent aggregated on the surface of the thrombus of the rabbit femoral arterial. The thrombus emitted fluorescence.

Conclusions

The binding rate of the targeted contrast agent prepared by 1:1 of urokinase/RGDS was the highest. It had thrombolysis ability in vitro, and it had thrombo-targeting effect in vivo.     

Regioselective synthesis and initial evaluation of a folate receptor targeted rhaponticin prodrug

To improve the therapeutic effect of rhaponticin(RHA),a folate receptor(FR) targeted RHA prodrug was designed and regioselectively synthesized by utilizing a hydrophilic peptide spacer linked to folic acid(FA) via a releasable disulfide linker.A series of biological evaluation was investigated in vitro and in vivo.The positive results of biological investigations warrant further preclinical study before this novel targeted chemotherapeutic is considered for clinical investigation.     

Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy

A new class of multifunctional nanoparticles that combine properties of polymeric drug carriers, ultrasound imaging contrast agents, and enhancers of ultrasound-mediated drug delivery has been developed. At room temperature, the developed systems comprise perfluorocarbon nanodroplets stabilized by the walls made of biodegradable block copolymers. Upon heating to physiological temperatures, the nanodroplets convert into nano/microbubbles. The phase state of the systems and bubble size may be controlled by the copolymer/perfluorocarbon volume ratio. Upon intravenous injections, a long-lasting, strong and selective ultrasound contrast is observed in the tumor volume indicating nanobubble extravasation through the defective tumor microvasculature, suggesting their coalescence into larger, highly echogenic microbubbles in the tumor tissue. Under the action of tumor-directed ultrasound, microbubbles cavitate and collapse resulting in a release of the encapsulated drug and dramatically enhanced intracellular drug uptake by the tumor cells. This effect is tumor-selective; no accumulation of echogenic microbubbles is observed in other organs. Effective chemotherapy of the MDA MB231 breast cancer tumors has been achieved using this technique.     

Optimal Halbach permanent magnet designs for maximally pulling and pushing nanoparticles

Optimization methods are presented to design Halbach arrays to maximize the forces applied on magnetic nanoparticles at deep tissue locations. In magnetic drug targeting, where magnets are used to focus therapeutic nanoparticles to disease locations, the sharp fall off of magnetic fields and forces with distances from magnets has limited the depth of targeting. Creating stronger forces at a depth by optimally designed Halbach arrays would allow treatment of a wider class of patients, e.g. patients with deeper tumors. The presented optimization methods are based on semi-definite quadratic programming, yield provably globally optimal Halbach designs in 2 and 3-dimensions, for maximal pull or push magnetic forces (stronger pull forces can collect nanoparticles against blood forces in deeper vessels; push forces can be used to inject particles into precise locations, e.g. into the inner ear). These Halbach designs, here tested in simulations of Maxwell's equations, significantly outperform benchmark magnets of the same size and strength. For example, a 3-dimensional 36 element 2000 cm³ volume optimal Halbach design yields a 5× greater force at a 10 cm depth compared to a uniformly magnetized magnet of the same size and strength. The designed arrays should be feasible to construct, as they have a similar strength (≤1 T), size (≤2000 cm³), and number of elements (≤36) as previously demonstrated arrays, and retain good performance for reasonable manufacturing errors (element magnetization direction errors ≤5°), thus yielding practical designs to improve magnetic drug targeting treatment depths.     

Intra-arterial application of magnetic nanoparticles for targeted thrombolytic therapy: A rat embolic model

Targeted delivery of thrombolytic drug to the site of emboli exhibits potential to greatly reduce hemorrhagic side effect. A rat embolic model with an easy access of a magnet was established for study of the efficacy of magnetic drug targeting. In anesthetized rats, a whole blood clot produced in vitro was injected from the right iliac artery and lodged in the left iliac artery. Intra-arterial infusion of recombinant tissue plasminogen activator (rt-PA) thereafter significantly reversed the iliac flow within 15 min. Placement of an NdFeB magnet above the left iliac artery caused magnetic nanoparticle retention against hemodynamic dragging force in the presence and absence of the clot. Our results suggest the feasibility of this rat embolic model for the study of magnetic targeted delivery of thrombolytic drugs.     

Periodic orbits, damped transitions and targeted energy transfers in oscillators with vibro-impact attachments

We study complex damped and undamped dynamics and targeted energy transfers (TETs) in systems of coupled oscillators, consisting of single-degree-of-freedom primary linear oscillators (LOs) with vibro-impact attachments, acting, in essence, as vibro-impact nonlinear energy sinks (VI NESs). First, the complicated dynamics of such VI systems is demonstrated by computing the VI periodic orbits of underlying Hamiltonian systems and depicting them in appropriate frequency–energy plots (FEPs). Then, VI damped transitions and distinct ways of passive TETs from the linear oscillators to the VI attachments for various parameter ranges and initial conditions are investigated. As in the case of smooth stiffness nonlinearity [Y. Lee, G. Kerschen, A. Vakakis, P. Panagopoulos, L. Bergman, D.M. McFarland, Complicated dynamics of a linear oscillator with a light, essentially nonlinear attachment, Physica D 204 (1–2) (2005) 41–69], both fundamental and subharmonic TET can be realized in the VI systems under consideration. It is found that the most efficient mechanism for VI TET is through the excitation of highly energetic VI impulsive orbits (IOs), i.e., of periodic or quasiperiodic orbits corresponding to zero initial conditions except for the initial velocities of the linear oscillators. In contrast to NESs with smooth essential nonlinearities considered in previous works, VI NESs are capable of passively absorbing and locally dissipating significant portions of the energies of the primary systems to which they are attached, at fast time scale. This renders such devices suitable for applications, like seismic mitigation, where dissipation of vibration energy in the early, highly energetic regime of the motion is a critical requirement.     

HILIC-MS/MS method development for targeted quantitation of metabolites: practical considerations from a clinical diagnostic perspective

The development of targeted assays for polar molecules is a persistent challenge in quantitative metabolite measurement. In addressing these challenges, hydrophilic interaction liquid chromatography (HILIC) has proved to be a valuable, though under-used and poorly understood chromatographic technique. This work has addressed a number of components that are intrinsic in development of a high-throughput, specific and sensitive assay for metabolites using HILIC-MS/MS. Generally accepted HILIC doctrine, such as addition of water to all mobile phases and re-equilibration time, was shown to be flawed under gradient HILIC mode. The effect of non-classical mobile phase additives on HILIC-MS/MS specificity, sensitivity and assay throughput was shown for endogenous metabolites. A broad evaluation of columns and mobile phases for the retention of varied molecular classes was performed, elucidating the empirical nature of HILIC method development. Application of the empirical evaluations performed in the paper was demonstrated by detailing a method development cycle for methylmalonic acid to achieve a highly selective and sensitive HILIC-MS/MS quantitation capable of high-throughput analysis for clinical utility.